A comprehensive review of interventions in the NOD mouse and implications for translation.

Type 1 diabetes (T1D) animal models such as the nonobese diabetic (NOD) mouse have improved our understanding of disease pathophysiology, but many candidate therapeutics identified therein have failed to prevent/cure human disease. We have performed a comprehensive evaluation of disease-modifying agents tested in the NOD mouse based on treatment timing, duration, study length, and efficacy. Interestingly, some popular tenets regarding NOD interventions were not confirmed: all treatments do not prevent disease, treatment dose and timing strongly influence efficacy, and several therapies have successfully treated overtly diabetic mice. The analysis provides a unique perspective on NOD interventions and suggests that the response of this model to therapeutic interventions can be a useful predictor of the human response as long as careful consideration is given to treatment dose, timing, and protocols; more thorough investigation of these parameters should improve clinical translation.

[1]  L. Adorini,et al.  IL-12 Administration Accelerates Autoimmune Diabetes in Both Wild-Type and IFN-γ-Deficient Nonobese Diabetic Mice, Revealing Pathogenic and Protective Effects of IL-12-Induced IFN-γ1 , 2003, The Journal of Immunology.

[2]  E. W. Heineke,et al.  Antioxidant MDL 29,311 Prevents Diabetes in Nonobese Diabetic and Multiple Low-Dose STZ-Injected Mice , 1993, Diabetes.

[3]  M. Kasuga,et al.  Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice. , 1998, Clinical immunology and immunopathology.

[4]  H. Weiner,et al.  Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. , 2001, International immunology.

[5]  R. Tisch,et al.  Plasmid DNAs Encoding Insulin and Glutamic Acid Decarboxylase 65 Have Distinct Effects on the Progression of Autoimmune Diabetes in Nonobese Diabetic Mice1 , 2001, The Journal of Immunology.

[6]  A. Signore,et al.  Standardizing experiments with NOD mice. , 1996, Autoimmunity.

[7]  H. Mcdevitt,et al.  Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Atkinson,et al.  Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy , 1990, Diabetes.

[9]  M. Suko,et al.  Preventive effects of Cyclosporin on diabetes in NOD mice , 1986, Diabetologia.

[10]  S. Pek,et al.  Prevention of Insulitis and Diabetes Onset by Treatment With Complete Freund's Adjuvant in NOD Mice , 1991, Diabetes.

[11]  M. Atkinson,et al.  Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes , 2004, Nature Reviews Immunology.

[12]  L. Theill,et al.  Polyethylene glycolated recombinant TNF receptor I improves insulitis and reduces incidence of spontaneous and cyclophosphamide-accelerated diabetes in nonobese diabetic mice. , 2002, Endocrinology.

[13]  J. Krischer,et al.  Therapeutic controversy: prevention and treatment of diabetes in children. , 2000, The Journal of clinical endocrinology and metabolism.

[14]  A. Laupacis,et al.  CYCLOSPORIN PREVENTS DIABETES IN BB WISTAR RATS , 1983, The Lancet.

[15]  中山 真紀.  Fas/Fas ligand interactions play an essential role in the initiation of murine autoimmune diabetes , 2002 .

[16]  C. Szabó,et al.  An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in NOD mice. , 2001, Journal of autoimmunity.

[17]  T. Saruta,et al.  Suppression of development of diabetes in NOD mice by lactate dehydrogenase virus infection. , 1992, Journal of autoimmunity.

[18]  J. Miyazaki,et al.  Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. , 1998, Human gene therapy.

[19]  I Mahmood,et al.  Allometric issues in drug development. , 1999, Journal of pharmaceutical sciences.

[20]  D. Cohen,et al.  Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. , 1997, The Journal of clinical investigation.

[21]  H. Kolb,et al.  The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. , 1998, Diabetes.

[22]  L. Chatenoud,et al.  Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Yamagata,et al.  Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice , 1990, Diabetologia.

[24]  R. Tisch,et al.  Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process , 1994, The Journal of experimental medicine.

[25]  H. Jun,et al.  Gamma interferon paradoxically inhibits the development of diabetes in the NOD mouse. , 2002, Journal of autoimmunity.

[26]  P. Nickerson,et al.  A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. , 1997, Journal of immunology.

[27]  J. Bach,et al.  Anti‐suppressor effect of cyclophosphamide on the development of spontaneous diabetes in nod mice , 1988, European journal of immunology.

[28]  F. Nicoletti,et al.  Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. , 2000, Endocrinology.

[29]  L. Chatenoud,et al.  Tolerance to islet autoantigens in type 1 diabetes. , 2001, Annual review of immunology.

[30]  H. Chase,et al.  Cyclosporine A for the treatment of new-onset insulin-dependent diabetes mellitus. , 1990, Pediatrics.

[31]  P. Santamaria,et al.  In situ beta cell death promotes priming of diabetogenic CD8 T lymphocytes. , 2002, Journal of immunology.

[32]  C. Fathman,et al.  Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. , 1988, Science.

[33]  N. Doll,et al.  High dose nicotinamide fails to prevent diabetes in BB rats. , 1989, Autoimmunity.

[34]  J. Bluestone,et al.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.

[35]  Y. W. Kim,et al.  Inhibition of diabetes in non-obese diabetic mice by nicotinamide treatment for 5 weeks at the early age. , 1997, Journal of Korean medical science.

[36]  M. Sadelain,et al.  Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. , 1993, Journal of immunology.

[37]  F. Nicoletti,et al.  Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. , 1995, Immunology.

[38]  D. Scott,et al.  Gene Transfer of Ig-Fusion Proteins Into B Cells Prevents and Treats Autoimmune Diseases1 , 2002, The Journal of Immunology.

[39]  Irun R Cohen,et al.  Hsp60 Peptide Therapy of NOD Mouse Diabetes Induces a Th2 Cytokine Burst and Downregulates Autoimmunity to Various β-Cell Antigens , 1997, Diabetes.

[40]  K. Buschard,et al.  Effect of intrathymic administration of mycobacterial heat shock protein 65 and peptide p277 on the development of diabetes in NOD mice: caution required in vaccination studies , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[41]  W. Ogawa,et al.  Prevention of Cyclophosphamide-Induced and Spontaneous Diabetes in NOD/Shi/Kbe Mice by Anti-MHC Class I Kd Monoclonal Antibody , 1991, Diabetes.

[42]  A. Rosenbloom.  Prevention of Type 1 Diabetes: Perspectives , 2000 .

[43]  J. Pléau,et al.  Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65). , 1995, Clinical immunology and immunopathology.

[44]  K. Haskins,et al.  Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. , 1990, Science.

[45]  C. Boitard,et al.  Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial , 2000, The Lancet.

[46]  A. Signore,et al.  Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse , 1993, Diabetologia.

[47]  H. Jun,et al.  A new type of CD4+ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. , 1996, Journal of autoimmunity.

[48]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[49]  J. Lohr,et al.  The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens , 2003, Nature Immunology.

[50]  H. Weiner,et al.  Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  C Benoist,et al.  T helper cell subsets in insulin-dependent diabetes. , 1995, Science.

[52]  A. Rivereau,et al.  Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments. Comparative efficiency of human insulin and two bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. , 1996, Diabetes & metabolism.

[53]  L. Harrison,et al.  Increase in Remission Rate in Newly Diagnosed Type I Diabetic Subjects Treated with Azathioprine , 1985, Diabetes.

[54]  R. Wu,et al.  The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice , 2002, Diabetologia.

[55]  G. Soma,et al.  Homeostasis as regulated by activated macrophage. V. Suppression of diabetes mellitus in non-obese diabetic mice by LPSw (a lipopolysaccharide from wheat flour). , 1992, Chemical & pharmaceutical bulletin.

[56]  S. Henderson,et al.  Prevention of a Thl Disease by a Thl, Cytokine: IL‐12 and Diabetes in, NOD Mice , 1996 .

[57]  C. Boitard,et al.  Long-Term Results of Early Cyclosporin Therapy in Juvenile IDDM , 1996, Diabetes.

[58]  J. Miyazaki,et al.  Systemic Administration of IL-18 Promotes Diabetes Development in Young Nonobese Diabetic Mice , 2003, The Journal of Immunology.

[59]  C. Peterson,et al.  Dapsone at onset of diabetes lowers glycated hemoglobin and delays death in NOD mice. , 1998, Autoimmunity.

[60]  S. Sandler,et al.  Protection against hyperglycemia in female nonobese diabetic mice treated with 15-deoxyspergualin. , 1992, Autoimmunity.

[61]  A. T. N. Group,et al.  No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII) , 2000, Diabetologia.

[62]  L. Mouthon,et al.  Polyreactive Autoantibodies Purified from Human Intravenous Immunoglobulins Prevent the Development of Experimental Autoimmune Diseases , 2003, Laboratory Investigation.

[63]  T. Seemayer,et al.  Diabetes prevention in BB rats by inhibition of endogenous insulin secretion. , 1991, Metabolism: clinical and experimental.

[64]  G. Prud’homme,et al.  Intramuscular administration of expression plasmids encoding interferon‐γ receptor/IgG1 or IL‐4/IgG1 chimeric proteins protects from autoimmunity , 1999, The journal of gene medicine.

[65]  T. Hanafusa,et al.  Preventive and Therapeutic Effects of Large-Dose Nicotinamide Injections on Diabetes Associated with Insulitis: An Observation in Nonobese Diabetic (NOD) Mice , 1982, Diabetes.

[66]  A Jaramillo,et al.  Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice , 1993, The Journal of experimental medicine.

[67]  H. Toyoda,et al.  Effect of 5-α Dihydrotestosterone on T-cell Proliferation of the Female Nonobese Diabetic Mouse , 1996, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[68]  D. Greiner,et al.  Rat models of type 1 diabetes: genetics, environment, and autoimmunity. , 2004, ILAR journal.

[69]  J. Peterson,et al.  Transfer of Diabetes in the NOD-scid Mouse by CD4 T-Cell Clones: Differential Requirement for CD8 T-Cells , 1996, Diabetes.

[70]  H. Kolb,et al.  IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis. , 1999, Journal of immunology.

[71]  D. Schoenfeld,et al.  Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. , 2001, The Journal of clinical investigation.

[72]  R. Tisch,et al.  CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. , 1997, Journal of immunology.

[73]  C. Janeway,et al.  Prevention of Diabetes in NOD Mice by Injection of Autoreactive T-Lymphocytes , 1989, Diabetes.

[74]  M. Harada,et al.  Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. , 1990, Diabetes research and clinical practice.

[75]  R. Tisch,et al.  Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice , 1993, Nature.

[76]  S. Khoury,et al.  The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice , 2003, The Journal of experimental medicine.

[77]  C. Boitard,et al.  Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. , 2000, Lancet.

[78]  A. Cooke,et al.  Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent onset of type 1 diabetes , 2003, European journal of immunology.

[79]  Linrong Lu,et al.  Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[80]  D. Vergani,et al.  Lymphocyte vaccination prevents spontaneous diabetes in the non-obese diabetic mouse. , 1993, Immunology.

[81]  M. Oldstone.  Viruses as therapeutic agents. I. Treatment of nonobese insulin- dependent diabetes mice with virus prevents insulin-dependent diabetes mellitus while maintaining general immune competence , 1990, The Journal of experimental medicine.

[82]  J. Petersen,et al.  A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[83]  K. Hamaguchi,et al.  Immunostimulation circumvents diabetes in NOD/Lt mice. , 1989, Journal of autoimmunity.

[84]  Meng Chen,et al.  The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice. , 2003, Clinical immunology.

[85]  T. Flotte,et al.  Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[86]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[87]  J. Bluestone,et al.  Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells 1 , 2003, The Journal of Immunology.

[88]  I. Cohen,et al.  Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies. , 1997, Journal of autoimmunity.

[89]  R. Elliott,et al.  Early nicotinamide treatment in the NOD mouse: effects on diabetes and insulitis suppression and autoantibody levels. , 1990, Diabetes research.

[90]  I. Cohen,et al.  Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[91]  A. Renold,et al.  Gangliosides in vivo reduce diabetes incidence in non-obese diabetic mice , 1988, Diabetologia.

[92]  L. Adorini,et al.  Deviation of pancreas‐infiltrating cells to Th2 by interleukin‐12 antagonist administration inhibits autoimmune diabetes , 1997, European journal of immunology.

[93]  T. Matsuzaki,et al.  Prevention of onset in an insulin‐dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[94]  M. Fujimiya,et al.  Extrapancreatic insulin-producing cells in multiple organs in diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[95]  N. Maclaren,et al.  Antigen based therapies to prevent diabetes in NOD mice. , 1996, Journal of autoimmunity.

[96]  J. Y. Kim,et al.  Effects of BCG, lymphotoxin and bee venom on insulitis and development of IDDM in non-obese diabetic mice. , 1999, Journal of Korean medical science.

[97]  I. Cohen,et al.  Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. , 2001, Lancet.

[98]  H. DeLuca,et al.  Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. , 2003, Archives of biochemistry and biophysics.

[99]  Cyclosporin-Induced Remission of IDDM After Early Intervention: Association of 1 yr of Cyclosporin Treatment With Enhanced Insulin Secretion , 1988, Diabetes.

[100]  A. Cooke,et al.  Thymus‐dependent monoclonal antibody‐induced protection from transferred diabetes , 1998, European journal of immunology.

[101]  M. Monahan,et al.  Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. , 1994, Clinical immunology and immunopathology.

[102]  K. Buschard,et al.  Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals , 1985, Diabetologia.

[103]  M. Kurrer,et al.  T Helper 2 (Th2) T Cells Induce Acute Pancreatitis and Diabetes in Immune-compromised Nonobese Diabetic (NOD) Mice , 1997, The Journal of experimental medicine.

[104]  Meng Chen,et al.  Suppression of Autoimmune Diabetes by Viral IL-10 Gene Transfer1 , 2002, The Journal of Immunology.

[105]  K. Amano,et al.  Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. , 1996, Journal of immunology.

[106]  Asaf Rotem,et al.  Vaccination with Empty Plasmid DNA or CpG Oligonucleotide Inhibits Diabetes in Nonobese Diabetic Mice: Modulation of Spontaneous 60-kDa Heat Shock Protein Autoimmunity1 , 2000, The Journal of Immunology.

[107]  T. Maki,et al.  Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[108]  M. Atkinson,et al.  Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes , 1996, The Journal of experimental medicine.

[109]  M. Kasuga,et al.  Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. , 2000, Diabetes.

[110]  E. Bonifacio,et al.  Delayed exposure to wheat and barley proteins reduces diabetes incidence in non-obese diabetic mice. , 2004, Clinical immunology.

[111]  D. Harlan,et al.  A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.

[112]  H. Kolb,et al.  Meta-Analysis of Nicotinamide Treatment in Patients With Recent-Onset IDDM , 1996, Diabetes Care.

[113]  A. Hayward,et al.  Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. , 1989, Journal of immunology.

[114]  P. Bedossa,et al.  Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. , 1991, European journal of immunology.

[115]  T. Maki,et al.  Regulation of autoimmune diabetes by interleukin 3-dependent bone marrow-derived cells in NOD mice. , 1997, Journal of autoimmunity.

[116]  M. Atkinson.  Heat shock protein therapy fails to prevent diabetes in NOD mice , 2002, Diabetologia.

[117]  P. Bedossa,et al.  CD8+ T cell homing to the pancreas in the nonobese diabetic mouse is CD4+ T cell-dependent. , 1991, Journal of immunology.

[118]  S. Baekkeskov,et al.  Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL‐4 increases safety , 2002, European journal of immunology.

[119]  C. Mathieu,et al.  Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A. , 1998, Endocrinology.

[120]  M. Atkinson,et al.  Acceleration of type 1 diabetes by a coxsackievirus infection requires a preexisting critical mass of autoreactive T-cells in pancreatic islets. , 2000, Diabetes.

[121]  L. Martignat,et al.  Neonatal injections of cyclosporin enhance autoimmune diabetes in non‐obese diabetic mice , 1994, Clinical and experimental immunology.

[122]  P. Pozzilli,et al.  No effect of oral insulin on residual beta-cell function in recent onset type 1 diabetes , 2000 .

[123]  A. Isacchi,et al.  Early Th1 Response in Unprimed Nonobese Diabetic Mice to the Tyrosine Phosphatase-Like Insulinoma-Associated Protein 2, an Autoantigen in Type 1 Diabetes , 2000, The Journal of Immunology.

[124]  C. Mathieu,et al.  Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3 , 1994, Diabetologia.

[125]  J. Sredy,et al.  Rapamycin prevents the onset of insulin‐dependent diabetes mellitus (IDDM) in NOD mice , 1992, Clinical and experimental immunology.

[126]  K. Haskins,et al.  Induction of Diabetes in Nonobese Diabetic Mice by Th2 T Cell Clones from a TCR Transgenic Mouse1 , 2000, The Journal of Immunology.

[127]  The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse. , 1996, Endocrinology.

[128]  C. Peterson,et al.  Dapsone Decreases the Cumulative Incidence of Diabetes in Non-Obese Diabetic Female Mice , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[129]  P. Morel,et al.  Immunobiology of DC in NOD mice , 1999, Journal of leukocyte biology.

[130]  L. Chatenoud,et al.  METABOLIC AND IMMUNOLOGICAL EFFECTS OF CYCLOSPORIN IN RECENTLY DIAGNOSED TYPE 1 DIABETES MELLITUS , 1985, The Lancet.

[131]  H. Mcdevitt,et al.  Tumor necrosis factor-α regulation of CD4+C25+ T cell levels in NOD mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[132]  J. Petersen,et al.  Immunization of diabetes-prone or non-diabetes-prone mice with GAD65 does not induce diabetes or islet cell pathology. , 1998, Journal of autoimmunity.

[133]  A. Rabinovitch,et al.  Lazaroid antioxidant reduces incidence of diabetes and insulitis in nonobese diabetic mice. , 1993, The Journal of laboratory and clinical medicine.

[134]  C. Peterson,et al.  Effects of low-dose cyclosporine prophylaxis in nonobese diabetic mice. , 1987, The Journal of pharmacology and experimental therapeutics.

[135]  M. Sadelain,et al.  Prevention of Type I Diabetes in NOD Mice by Adjuvant Immunotherapy , 1990, Diabetes.

[136]  L. Chatenoud,et al.  CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. , 1997, Journal of immunology.

[137]  J. Krischer,et al.  Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. , 2005, Diabetes care.

[138]  J. Krischer,et al.  Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. , 1995, The Journal of clinical investigation.

[139]  A. Naji,et al.  B-Cells Are Required for the Initiation of Insulitis and Sialitis in Nonobese Diabetic Mice , 1997, Diabetes.

[140]  H. Garren,et al.  Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. , 2001, Clinical immunology.

[141]  M. Matsumoto,et al.  Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mouse. II. Suppression of pathogenesis by macrophage transfer from BCG-vaccinated mice. , 1991, Cellular immunology.

[142]  E. Niki,et al.  Prevention of Type I Diabetes by Low-Dose Gamma Irradiation in NOD Mice , 2000, Radiation research.

[143]  M. Atkinson,et al.  Retardation or Acceleration of Diabetes in NOD/Lt Mice Mediated by Intrathymic Administration of Candidate β-Cell Antigens , 1997, Diabetes.

[144]  D. Guberski,et al.  Spontaneous Diabetes Mellitus in the BB/W Rat: Effects of Glucocorticoids, Cyclosporin-A, and Antiserum to Rat Lymphocytes , 1983, Diabetes.

[145]  M. Sadelain,et al.  Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. , 1990, Journal of autoimmunity.

[146]  S. W. Kim,et al.  Anti-GAD Monoclonal Antibody Delays the Onset of Diabetes Mellitus in NOD Mice , 1999, Pharmaceutical Research.

[147]  C. Hales,et al.  IMPROVEMENT IN INSULIN SECRETION IN DIABETES AFTER DIAZOXIDE , 1976, The Lancet.

[148]  G. Prud’homme,et al.  The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. , 1998, Diabetes.

[149]  M. Peppa,et al.  Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. , 2003, Diabetes.

[150]  C. Thivolet,et al.  Active Suppression of Diabetes after Oral Administration of Insulin Is Determined by Antigen Dosage , 1996, Annals of the New York Academy of Sciences.

[151]  C. Szabó,et al.  Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. , 2003, Diabetes.

[152]  G. Szot,et al.  Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. , 2004, The Journal of clinical investigation.

[153]  L. Chatenoud,et al.  [Remission of established disease in diabetic NOD mice induced by anti-CD3 monoclonal antibody]. , 1992, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[154]  A. Cooke,et al.  In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice. , 1995, The Journal of clinical investigation.

[155]  Y. Tochino,et al.  Breeding of a non-obese, diabetic strain of mice. , 1980, Jikken dobutsu. Experimental animals.

[156]  E. Bonifacio,et al.  Pancreatic β-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 Diabetes , 2004 .

[157]  J. Ferrara,et al.  CD4+ beta islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice , 1995, The Journal of experimental medicine.

[158]  L. Chatenoud,et al.  Long-Term Reversal of Established Autoimmunity upon Transient Blockade of the LFA-1/Intercellular Adhesion Molecule-1 Pathway1 , 2002, The Journal of Immunology.

[159]  N. Chapman,et al.  Toward Testing the Hypothesis that Group B Coxsackieviruses (CVB) Trigger Insulin-Dependent Diabetes: Inoculating Nonobese Diabetic Mice with CVB Markedly Lowers Diabetes Incidence , 2002, Journal of Virology.

[160]  M. Ikeda,et al.  Oral use of interferon-alpha delays the onset of insulin-dependent diabetes mellitus in nonobese diabetes mice. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[161]  R. Tisch,et al.  Antigen-Specific Mediated Suppression of β Cell Autoimmunity by Plasmid DNA Vaccination1 , 2001, The Journal of Immunology.

[162]  S. Henderson,et al.  Prevention of a Th1 disease by a Th1 cytokine: IL-12 and diabetes in NOD mice. , 1996, Annals of the New York Academy of Sciences.

[163]  L. Harrison,et al.  Aerosol Insulin Induces Regulatory CD8 γδ T Cells That Prevent Murine Insulin-dependent Diabetes , 1996, The Journal of experimental medicine.

[164]  Hyun Chul Lee,et al.  Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue , 2000, Nature.

[165]  A. Hayward,et al.  Reduced incidence of insulitis in NOD mice following anti-CD3 injection: requirement for neonatal injection. , 1992, Journal of autoimmunity.

[166]  C. Boitard,et al.  Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells , 1987, The Journal of experimental medicine.

[167]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[168]  Yuxin Lu,et al.  Lipopolysaccharide-Activated B Cells Down-Regulate Th1 Immunity and Prevent Autoimmune Diabetes in Nonobese Diabetic Mice1 , 2001, The Journal of Immunology.

[169]  J. Elliott,et al.  Effect of Bacille Calmette-Guérin Vaccination on C-Peptide Secretion in Children Newly Diagnosed With IDDM , 1998, Diabetes Care.

[170]  I. Cohen,et al.  Treatment of Autoimmune Diabetes and Insulitis in NOD Mice With Heat Shock Protein 60 Peptide p277 , 1995, Diabetes.

[171]  B. Charbonnel,et al.  Diabetes enhancement and increased islet antigen expression following neonatal injections of glucose and arginine in non-obese diabetic mice. , 1994, Metabolism: clinical and experimental.

[172]  J. Bluestone,et al.  Reversal of Spontaneous Autoimmune Insulitis in Nonobese Diabetic Mice by Soluble Lymphotoxin Receptor , 2001, The Journal of experimental medicine.

[173]  J. Satoh,et al.  Inhibition of autoimmune diabetes in NOD mice with serum from streptococcal preparation (OK‐432)‐injected mice , 1991, Clinical and experimental immunology.

[174]  Peter Lipsky,et al.  Cytokines and autoimmunity , 2002, Nature Reviews Immunology.

[175]  D. Harlan,et al.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[176]  T. Kalland,et al.  Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug , 1994, Diabetologia.

[177]  J. Bluestone,et al.  TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes , 2003, Nature Medicine.

[178]  C. Boitard,et al.  Passive transfer of flt‐3L‐derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin (IL)‐4 and IL‐10 in the spleen of recipient mice , 2003, Clinical and experimental immunology.

[179]  J. Petersen,et al.  Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. , 1999, Journal of immunology.

[180]  C. Ferran,et al.  DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY CURES NEW-ONSET DIABETES, PREVENTS RECURRENT AUTOIMMUNE DIABETES, AND DELAYS ALLOGRAFT REJECTION IN NONOBESE DIABETIC MICE1 , 2004, Transplantation.

[181]  C. Piccirillo,et al.  TGF-beta1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. , 1998, Journal of immunology.

[182]  A. Cooke,et al.  Interleukin-13 prevents autoimmune diabetes in NOD mice. , 1999, Diabetes.

[183]  I. Cohen,et al.  Peptide therapy for diabetes in NOD mice , 1994, The Lancet.

[184]  H. Okamura,et al.  Prevention of diabetes in non-obese diabetic mice by a single immunization with Mycobacterium leprae. , 2002, Nihon Hansenbyo Gakkai zasshi = Japanese journal of leprosy : official organ of the Japanese Leprosy Association.

[185]  J. B. Classen,et al.  The timing of immunization affects the development of diabetes in rodents. , 1996, Autoimmunity.

[186]  H. Kolb,et al.  Oral insulin for diabetes prevention in NOD mice: potentiation by enhancing Th2 cytokine expression in the gut through bacterial adjuvant , 1997, Diabetologia.

[187]  H. Kolb,et al.  Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats , 1998, Diabetologia.

[188]  A. Signore,et al.  Reduced cumulative incidence of diabetes but not insulitis following administration of chimeric human IL‐15–murine IgG2b in NOD mice , 2003, Diabetes/metabolism research and reviews.

[189]  M. Patti,et al.  High-fructose diet preserves beta-cell mass and prevents diabetes in nonobese diabetic mice: A potential role for increased insulin receptor substrate-2 expression. , 2001, Metabolism: clinical and experimental.

[190]  Y. Matsuzawa,et al.  The NOD mouse. , 1994, Diabetes research and clinical practice.

[191]  G. Werther,et al.  Double-Blind Controlled Trial of Azathioprine in Children With Newly Diagnosed Type I Diabetes , 1989, Diabetes.

[192]  M. Cameron,et al.  Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer , 2000, Gene Therapy.

[193]  E. Sercarz,et al.  MHC Class I-Restricted Determinants on the Glutamic Acid Decarboxylase 65 Molecule Induce Spontaneous CTL Activity1 , 2001, The Journal of Immunology.

[194]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.

[195]  C. Ricordi,et al.  Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation. , 2001, Diabetes.

[196]  M. Atkinson,et al.  Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice , 2004, Gene Therapy.

[197]  R. Lustig,et al.  Pentoxifylline in the treatment of children with new-onset type I diabetes mellitus. , 1994, JAMA.

[198]  M. Dardenne,et al.  Environmental and experimental procedures leading to variations in the incidence of diabetes in the nonobese diabetic (NOD) mouse. , 1996, Autoimmunity.

[199]  M. Kronenberg,et al.  Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes , 2001, Nature Medicine.

[200]  A. Tobin,et al.  Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes–prone mice , 1996, Nature Medicine.

[201]  J. Petersen,et al.  Neonatal Tolerization With Glutamic Acid Decarboxylase But Not With Bovine Serum Albumin Delays the Onset of Diabetes in NOD Mice , 1994, Diabetes.

[202]  N. Maclaren,et al.  Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice. , 1997, Autoimmunity.

[203]  J. Satoh,et al.  Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. , 1989, The Journal of clinical investigation.

[204]  Mark S. Anderson,et al.  The NOD mouse: a model of immune dysregulation. , 2005, Annual review of immunology.

[205]  Stephen S. Wilson,et al.  Therapeutic Alteration of Insulin-Dependent Diabetes Mellitus Progression by T Cell Tolerance to Glutamic Acid Decarboxylase 65 Peptides In Vitro and In Vivo1 , 2001, The Journal of Immunology.

[206]  Bhagirath Singh,et al.  The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. , 1997, Immunity.

[207]  R. Tisch,et al.  A predominant role of integrin alpha 4 in the spontaneous development of autoimmune diabetes in nonobese diabetic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[208]  T. Flotte,et al.  Systemic Overexpression of IL-10 Induces CD4+CD25+ Cell Populations In Vivo and Ameliorates Type 1 Diabetes in Nonobese Diabetic Mice in a Dose-Dependent Fashion 1 , 2003, The Journal of Immunology.

[209]  G. Papaccio,et al.  Macrophages and antioxidant status in the NOD mouse pancreas , 1998, Journal of cellular biochemistry.

[210]  J. Habener,et al.  Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. , 2004, Diabetes.

[211]  E. Gale.  European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes , 2004, The Lancet.

[212]  K. Amano,et al.  Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice. , 1995, Cellular immunology.

[213]  Q. Mi,et al.  Perturbed Homeostasis of Peripheral T Cells Elicits Decreased Susceptibility to Anti-CD3-Induced Apoptosis in Prediabetic Nonobese Diabetic Mice1 , 2004, The Journal of Immunology.

[214]  H. Weiner,et al.  Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. , 1991 .

[215]  M. Charles,et al.  The effects of nicotinamide and glimepiride on diabetes prevention in BB rats. , 1995, Life sciences.

[216]  K. Wucherpfennig,et al.  Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. , 2004, The Journal of clinical investigation.

[217]  R. Tisch,et al.  Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. , 1999, Journal of immunology.

[218]  D. Wagner,et al.  Peripheral CD 4 loCD 40 + auto-aggressive T cell expansion during insulin-dependent diabetes mellitus , 2004 .

[219]  P. Bedossa,et al.  Role of CD4+CD45RA+ T cells in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse. , 1993, International immunology.

[220]  F. Calcinaro,et al.  Effect of adjuvant therapy on development of diabetes in mouse and man , 1994, The Lancet.

[221]  M. Lan,et al.  Immunization therapies in the prevention of diabetes. , 1997, Journal of Autoimmunity.

[222]  F. Nicoletti,et al.  Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in NOD mice. , 1999, Diabetes.

[223]  Meroni,et al.  Endogenous interleukin‐12 only plays a key pathogenetic role in non‐obese diabetic mouse diabetes during the very early stages of the disease , 1999, Immunology.

[224]  Simon C Watkins,et al.  Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. , 2003, Human gene therapy.

[225]  A. Mortara,et al.  Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice , 1995, The Journal of experimental medicine.

[226]  Jeffrey A. Bluestone,et al.  In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[227]  C. Boitard,et al.  Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial , 1998, Diabetologia.

[228]  H. Chase,et al.  Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. , 1999, Diabetes care.

[229]  Onji,et al.  Transfer of dendritic cells (DC) ex vivo stimulated with interferon‐gamma (IFN‐γ) down‐modulates autoimmune diabetes in non‐obese diabetic (NOD) mice , 1999, Clinical and experimental immunology.

[230]  P. Pozzilli,et al.  Cytokine profile and insulin antibody IgG subclasses in patients with recent onset Type 1 diabetes treated with oral insulin , 2004, Diabetologia.

[231]  A. M. Shapiro,et al.  Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice , 2002, Diabetologia.

[232]  P. Mottram,et al.  Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies. , 2002, Transplant immunology.

[233]  P. Brunetti,et al.  Preventive effects of azathioprine (AZA) on the onset of diabetes mellitus in NOD mice , 1993, Journal of endocrinological investigation.

[234]  M. Amato,et al.  The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. , 1990, Journal of autoimmunity.

[235]  S. Reddy,et al.  Prevention of autoimmune diabetes by oral administration of syngeneic pancreatic extract to young NOD mice. , 2000, Pancreas.

[236]  J. Satoh,et al.  Prevention of Autoimmune Diabetes with Lymphotoxin in NOD Mice , 1993, Diabetes.

[237]  W. Cefalu,et al.  Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.

[238]  C. Berne,et al.  Diazoxide Treatment at Onset Preserves Residual Insulin Secretion in Adults with Autoimmune Diabetes , 1996, Diabetes.

[239]  A. Rabinovitch,et al.  Combination therapy with an antioxidant and a corticosteroid prevents autoimmune diabetes in NOD mice. , 1992, Life sciences.

[240]  H. Weiner,et al.  Oral Insulin Does Not Prevent Insulin‐dependent Diabetes Melltus in BB Rats , 1996, Annals of the New York Academy of Sciences.

[241]  T. Hanafusa,et al.  Decreased incidence of diabetes mellitus by monosodium glutamate in the non-obese diabetic (NOD) mouse. , 1985, Research communications in chemical pathology and pharmacology.